相似文献
1
Guidelines for the labelling of leucocytes with (99m)Tc-HMPAO. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine.
Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):842-8. doi: 10.1007/s00259-010-1394-4.
2
Guidelines for the labelling of leucocytes with (111)In-oxine. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine.
Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):835-41. doi: 10.1007/s00259-010-1393-5.
3
An in vitro study to compare 99mTc-stannous colloids and 99mTc-HMPAO for labelling human leukocytes.
Q J Nucl Med Mol Imaging. 2004 Sep;48(3):229-36.
4
Media Fill Test for validation of autologous leukocytes separation and labelling by (99m)Tc-HmPAO.
Nucl Med Biol. 2013 Jan;40(1):104-8. doi: 10.1016/j.nucmedbio.2012.09.002. Epub 2012 Oct 15.
5
HMGB1 expression in leukocytes as a biomarker of cellular damage induced by [Tc]Tc-HMPAO-labelling procedure: A quality control study.
Nucl Med Biol. 2021 May-Jun;96-97:94-100. doi: 10.1016/j.nucmedbio.2021.03.008. Epub 2021 Apr 9.
6
Novel approach for quality assessment and improving diagnostic accuracy in cell-based infection imaging using 99mTc-HMPAO labeled leukocytes.
Acta Biomed. 2018 Oct 8;89(3):355-364. doi: 10.23750/abm.v89i3.7064.
7
New synthesis route of active substance d,l-HMPAO for preparation Technetium Tc99m Exametazime.
Nucl Med Rev Cent East Eur. 2017;20(2):88-94. doi: 10.5603/NMR.2017.0014.
8
Leukocyte labeling with 99mTc-HMPAO. The role of the in vitro stability of HMPAO on the labeling efficacy and image quality.
Nucl Med Biol. 1994 Aug;21(6):893-5. doi: 10.1016/0969-8051(94)90170-8.
9
A consensus protocol for white blood cells labelling with technetium-99m hexamethylpropylene amine oxime. International Society of Radiolabeled Blood Elements (ISORBE).
Eur J Nucl Med. 1998 Jul;25(7):797-9. doi: 10.1007/s002590050285.
10
Study of Binding Kinetics and Specificity of Tc-SSS-Complex and Tc-HMPAO to Blood Cells.
Contrast Media Mol Imaging. 2018 Oct 25;2018:5603902. doi: 10.1155/2018/5603902. eCollection 2018.
引用本文的文献
1
Fungal infections in focus: accelerating non-invasive imaging from preclinical insights to clinical breakthroughs.
Npj Imaging. 2025 Sep 16;3(1):42. doi: 10.1038/s44303-025-00105-y.
2
Radiolabeling isolated mitochondria with Tc-99m: A first-in-field protocol and early feasibility findings.
Biol Methods Protoc. 2025 Aug 9;10(1):bpaf063. doi: 10.1093/biomethods/bpaf063. eCollection 2025.
3
A Head-to-Head Comparison Between [F]Fluorodeoxyglucose ([F]FDG) Positron Emission Tomography/Computed Tomography (PET/CT) and Technetium-Hexamethylpropylene Amine Oxime (HMPAO)-Labeled Leukocyte Scintigraphy in a Case Series of Patients with Suspected Vascular Prosthesis Infection: To Trust Is Good, but to Check Is Better.
J Clin Med. 2025 Jun 18;14(12):4352. doi: 10.3390/jcm14124352.
4
Intracellular Protein Binding of Zr-89 Oxine Cell Labeling for PET Cell Tracking Studies.
Pharmaceutics. 2025 Apr 15;17(4):518. doi: 10.3390/pharmaceutics17040518.
5
Demonstrating an Academic Core Facility for Automated Medical Image Processing and Analysis: Workflow Design and Practical Applications.
Diagnostics (Basel). 2025 Mar 21;15(7):803. doi: 10.3390/diagnostics15070803.
6
Head-to-Head Comparison Between F-FDG PET and Leukocyte Scintigraphy to Monitor Treatment Responses in Necrotizing Otitis Externa.
J Otolaryngol Head Neck Surg. 2024 Jan-Dec;53:19160216241288810. doi: 10.1177/19160216241288810.
7
First-in-human infection imaging with Zr-labelled leukocytes and comparison of scan quality with [Tc]Tc-HMPAO-labelled leukocytes.
Front Nucl Med. 2024 Jul 22;4:1426650. doi: 10.3389/fnume.2024.1426650. eCollection 2024.
8
Contemporary Role of Positron Emission Tomography (PET) in Endocarditis: A Narrative Review.
J Clin Med. 2024 Jul 15;13(14):4124. doi: 10.3390/jcm13144124.
9
Bio-distribution study of Tc-99m HMPAO labeled platelet in healthy volunteer.
Asia Ocean J Nucl Med Biol. 2024;12(2):142-148. doi: 10.22038/AOJNMB.2024.71620.1525.
10
An overview of the current diagnostic approach to Periprosthetic Joint Infections.
Orthop Rev (Pavia). 2024 Jun 30;16:120308. doi: 10.52965/001c.120308. eCollection 2024.
本文引用的文献
1
Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals.
Eur J Nucl Med Mol Imaging. 2010 May;37(5):1049-62. doi: 10.1007/s00259-010-1407-3.
2
Ficoll-Paque versus Lymphoprep: a comparative study of two density gradient media for therapeutic bone marrow mononuclear cell preparations.
Regen Med. 2009 Sep;4(5):689-96. doi: 10.2217/rme.09.44.
3
Nuclear medicine imaging of diabetic foot infection: results of meta-analysis.
Nucl Med Commun. 2006 Oct;27(10):757-64. doi: 10.1097/01.mnm.0000230065.85705.b3.
4
Nuclear medicine imaging of bone infections.
Nucl Med Commun. 2006 Aug;27(8):633-44. doi: 10.1097/00006231-200608000-00006.
5
Fever of unknown origin, infection of subcutaneous devices, brain abscesses and endocarditis.
Nucl Med Commun. 2006 Mar;27(3):213-22. doi: 10.1097/00006231-200603000-00003.
6
Nuclear medicine imaging of inflammatory/infective disorders of the abdomen.
Nucl Med Commun. 2005 Jul;26(7):657-64. doi: 10.1097/01.mnm.0000169202.68011.47.
7
[Fast method of labelling leukocytes with 99mTc HM PAO].
Rev Esp Med Nucl. 2002 Sep-Oct;21(5):343-8. doi: 10.1016/s0212-6982(02)72105-8.
8
Labeling of mixed leukocytes with (99m)Tc-HMPAO causes severe chromosomal aberrations in lymphocytes.
J Nucl Med. 2002 Feb;43(2):203-6.
9
A consensus protocol for white blood cells labelling with technetium-99m hexamethylpropylene amine oxime. International Society of Radiolabeled Blood Elements (ISORBE).
Eur J Nucl Med. 1998 Jul;25(7):797-9. doi: 10.1007/s002590050285.
10
Oxido-reductive state: the major determinant for cellular retention of technetium-99m-HMPAO.
J Nucl Med. 1996 Aug;37(8):1413-6.
Zotero 插件